Obesity: The hormonal milieu

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 1, 2008, Pages 9-20

  Lenz, Anne ^a,b   Diamond Jr , Frank B ^a,b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Adipokine; Enteroendocrine hormone; Obesity; Satiety

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMYLIN; CHOLECYSTOKININ; ENTEROSTATIN; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; OBESTATIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PROOPIOMELANOCORTIN; VISFATIN;

ADIPOSE TISSUE; APPETITE; BODY COMPOSITION; BRAIN STEM; CALORIC INTAKE; ENDOCRINE GLAND; ENTEROENDOCRINE CELL; EPIDEMIC; FOOD COMPOSITION; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; VAGUS NERVE;

ADIPOCYTES; APPETITE REGULATION; ENDOCRINE SYSTEM; ENERGY METABOLISM; ENTEROENDOCRINE CELLS; FETAL DEVELOPMENT; HORMONES; HUMANS; MODELS, BIOLOGICAL; OBESITY;

EID: 38049151028     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f43a5b     Document Type: Review

References (145)

1. Ogden C, Carroll M, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
2. Migrenne S, Marsollier N, Cruciani-Guglielmacci C, Magnan C. Importance of the gut-brain axis in the control of glucose homeostasis. Curr Opin Pharmacol 2006; 6:592-597. Addresses the central processing of gut hormone signals at the hypothalamus. This article highlights ghrelin and GLP-1's new-found roles in glucose homeostasis and mechanisms of action through brainstem circuits.
3. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117:13-23. Comprehensive review of the role of gut peptides in control of appetite. Organizes peptide contributions to satiation based on anatomic site of origin for a concise but thorough overview of gut signals.
4. Badman MK, Flier J. The gut and energy balance: visceral allies in the obesity wars. Science 2005; 307:1909-1914.
5. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight reduced subjects. Nat Med 1995; l:1155-1161.
6. Satoh N, Ogawa Y, Katsuura G, et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 1999; 48:1787-1793.
7. Eckel LA, Langhans W, Kahler A, et al. Chronic administration of OB protein decreases food intake by selectively reducing meal size in female rats. Am J Physiol 1998; 275:R186-R193.
8. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356:237-247. A landmark study of leptin-receptor gene mutation in 300 subjects with hyperphagia and severe early-onset obesity, (90 of whom from consanguineous families). Three percent were found to have nonsense or missense LEPR mutations.
9. Dhillon H, Zigman JM, Ye C, et al. Leptin directly activates SF-1 neurons in the VMH and this action by leptin is required for normal body weight homeostasis. Neuron 2006; 49:191-203. An important study that reveals leptinergic reduction of body weight and induction of resistance to diet-induced obesity via activation of steroidogenic factor-l positive neurons in the ventromedial hypothalamus.
10. Elias CF, Aschkenasi C, Kelly J, et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 1999; 23:775-786.
11. Schwartz MW, Seeley RJ, Woods SC, et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997; 46:2119-2123.
12. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
13. Niimi M, Sato M, Taminato T, et al. Neuropeptide Y in central control of feeding and interactions with orexin and leptin. Endocrine 2001; 14:269-273.
14. Kikkotou EG, Tritos NA, Mastaitis JW, et al. Melanin-concentrating hormone receptor is a target of leptin action in the mouse brain. Endocrinology 2001; 142:680-686.
15. Schwartz GJ, Moran TH. Leptin and neropeptide y have opposing modulatory effects on nucleus of the solitary tract neurophysiological responses to gastric loads: implications for the control of food intake. Endocrinology 2002; 143:3779-3784.
16. Moran TH, Aja S, Ladenheim EE. Leptin modulation of peripheral controls of meal size. Physiol Behav 2006; 89:511-516. The study demonstrates how leptin extends its anorexigenic effects beyond the arcuate nucleus by facilitating cholecystokinin appetite signals to the dorsal hindbrain and nucleus of the tractus solitarius (NTS).
17. Cota D, Proulx K, Blake Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006; 312:927-930. A helpful review of the role of fuel-sensitive kinases in appetite regulation.
18. Lee MJ, Fried SK. Multilevel regulation of leptin storage, turnover and secretion by feeding and insulin in rat adipose tissue. J Lipid Res 2006; 47:1984-1993. Use of pulse-chase methodology to elucidate leptin production at multiple posttranscriptional steps including synthesis, storage degradation and secretion.
19. Uotani S, Bjorbaek C, Tornoe J, et al. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999; 48:279-286.
20. Ricci MR, Lee MJ, Russell CD, et al. Isoproterenol decreases leptin release from rat and human adipose tissue through posttranscriptional mechanisms. Am J Physiol Endocrinol Metab 2005; 288:E798-E804.
21. Bence KK, Delibegovic M, Bingzhong X, et al. Neuronal PTPlB regulates body weight, adiposity and leptin action. Nat Med 2006; 12:917-924. Using mouse knockout models of the tyrosine phosphatase PtPlB, neuronal as opposed to muscle or liver activity is shown to inhibit leptin action.
22. Gurierrez-Juarez R, Obici S, Rossetti L. Melanocortin independent effects of leptin on hepatic glucose fluxes. J Biol Chem 2004; 279:49704-49715.
23. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568-1575.
24. Kievit P, Howard JK, Badman MK, et al. Enhanced leptin were sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 2006; 4:123-132. This study is significant for demonstrating that targeting of Socs-3 deletion in hypothalamic cells expressing pro-opiomelanocortin improves glucose homeostasis in mice in the face of normal weight gain.
25. Stepanyan Z, Kocharyan A, Behrens M, et al. Somatostatin, a negative-regulator of central leptin action in the rat hypothalamus. J Neurochem 2007; 100:468-478. Reviews the recently reported role of somatostatin receptors in the regulation of central leptin action in the rat.
26. Chen K, Li J, Cai H, et al. Induction of leptin resistance through direct interaction of C-reactive protein. Nat Med 2006; 12:425-431. In-vitro and in-vivo experiments linking c-reactive protein to leptin resistance in mice. The study is significant as c-reactive protein is a commonly used clinical tool for assessing risk of atherosclerosis.
27. Adan RAH, Tiesjema B, Hillebrand JJG, et al. The MC4 receptor and control of appetite. Br J Pharmacol 2006; 149:815-827. Brings together newer information describing the brain site-specific signaling effects on food intake, fat intake and meal size.
28. Ste Marie L, Miura GI, Marsh DJ, et al. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 2000; 97:12339-12344.
29. Hinney A, Bettecken T, Tarnow P, et al. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab 2006; 91:1761-1769.
30. Lubrano-Berthelier C, Duber B, Lacorte JM, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 2006; 91:1811-1818.
31. Samama P, Rumennik L, Grippo JF. The melanocortin receptor MCR4 controls fat consumption. Regul Pept 2003; 113:85-88.
32. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-481.
33. Scherrer PE, Williams S, Fogliano M, et al. A novel serum protein similar to Clq produced exclusively in adipocytes. J Biol Chem 1995; 270:26746-26749.
34. Hotamisligil GS, Shargill NS, Spieglman BM. Adipocyte expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
35. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188:231-244. An excellent review of the genetics of adiponectin gene polymorphisms as well as adiponectin anti-inflammatory effects.
36. Buzzetti R, Petrone A, Zavarella S, et al. The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. Int J Obes 2007; 31:424-428.
37. Hara K, Horkoshi M, Yamauchi T, et al. Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29:1357-1362. Metabolic markers that predict insulin resistance may help clinicians anticipate and prevent metabolic syndrome/diabetes in higher risk patients. In this study of a large cohort of adults admitted for diabetes management or coronary angiography, the high molecular weight/total adiponectin ratio (HMWR), determined by ELISA, was more highly predictive of insulin resistance and metabolic syndrome that total adiponectin alone.
38. Saltiel AR. You are what you secrete. Nat Med 2001; 7:887-888.
39. Larson DE, Ferraro RT, Robertson DS, et al. Energy metabolism in weight-stable postobese individuals. Am J Clin Nutr 1995; 62:735-739.
40. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferators-activated receptor gamma agonists. J Biol Chem 2006; 281:2654-2660.
41. Ahima RS. Adipose tissue as an endocrine organ. Obesity 2006; 14:242S-249S.
42. Straczkowski M, Kowalska I, Nikolajuk A, et al. Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Int J Obes 2007; 31:221-225. The inverse relationship of serum IL-18 to adiponectin independent of confounding factors could suggest that lack of adiponectin suppression of this pro-inflammatory and pro-atherogenic cytokine contributes to insulin resistance in obese subjects.
43. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423:762-769.
44. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 5:524-529.
45. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:1917-1923.
46. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005; 307:366-367.
47. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
48. Arner P. Visfatin - A true or false trail to type 2 diabetes? J Clin Endocrinol Metab 2006; 91:28-30. A review of current understanding of visfatin that raises questions regarding its origin in visceral fat and its relationship to insulin sensitivity.
49. Hubler A, Rippel C, Kauf E, et al. Associations between ghrelin levels in serum of preterm infants and enteral nutrional state during the first 6 months after birth. Clin Endocrinol 2006; 65:611-616. Ghrelin is measured in preterm infants followed sequentially up to 6 months of age. Levels are related to the enteral nutritional state at 48 h of life and to the introduction of solid food at 6 months corrected age.
50. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 1999; 402:655-660.
51. Broglio F, Gottero C, Van KP, et al. Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab 2004; 89:2429-2433.
52. Bellone S, Castellino N, Broglio F, et al. Ghrelin secretion in childhood is refractory to the inhibitory effects of feeding. J Clin Endocrinol Metab 2004; 89:1662-1665.
53. Williams DL, Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 2005; 135:1320m-1325m.
54. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
55. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16:2111-2118.
56. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2832-2836.
57. MacKelvie K, Meneilly G, Wong ACK, et al. Exercise increases active ghrelin and appetite in lean but not obese male adolescents: relationship to testosterone. Horm Res 2005; 64:S376 [abstract].
58. Natalucci G, Riedl S, Gleiss A, et al. Spontaneous 24-h ghrelin secretion patterns in fasting subjects: maintenance of a meal-related pattern. Eur J Endocrinol 2005; 152:845-850.
59. Sugion T, Gasegawa Y, Kikkawa Y, et al. A transient ghrelin surge occurs just before feeding in a scheduled meal-fed sheep. Biochem Biophys Res Commun 2002; 295:255-260.
60. Theander-Carillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116:1983-1993. A review of ghrelin's actions on adipocyte metabolism independent of its hyperphagic effects including glucose utilization, fat storage, fatty acid oxidation and control of uncoupling proteins.
61. Coll AP, Farooqu S, O' Rahilly S. The hormonal control of food intake. Cell 2007; 129:251-262. Helpful discussion of downstream leptin effects and other brain appetite peptides including Single Minded-l (Sim1), brain derived neurotrophic factor (BDNF) and tyrosine kinase receptor (TrkB).
62. Higgins SC, Gueorguiev M, Korbonits M. Ghrelin, the peripheral hunger hormone. Ann Med 2007; 39:116-136.
63. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709.
64. Wortley KE, del Rincon JP, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preferences. Proc Natl Acad Sci USA 2004; 101:8227-8232.
65. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptor resist the development of diet induced obesity. J Clin Invest 2005; 115:3564-3572.
66. Bacha F, Arslanian SA. Ghrelin and peptide YY in youth: are there race-related differences? J Clin Endocrinol Metab 2006; 91:3117-3122. An important study that evaluates racial differences in postprandial ghrelin and PYY responses.
67. Banks WA, Tschop M, Robinson SM, et al. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002; 302:822-827.
68. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123:1120-1128.
69. Kohima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
70. Dhillo WS. Appetite Regulation: An Overview. Thyroid 2007; 17:433-445. A detailed review of factors controlling appetite with a particularly good discussion of the role of nutrients in appetite regulation.
71. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37:649-661.
72. Riediger T, Traebert M, Schmid HA, et al. Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett 2003; 341:151-155.
73. Murdolo G, Lucidi P, DiLorento C, et al. Insulin is required for prandial ghrelin suppression in humans. Diabetes 2003; 52:2923-2927.
74. Bacha F, Arslanian SA. Ghrelin suppression in overweight children: a manifestation of insulin resistance. J Clin Endocrinol Metab 2005; 90:2725-2730.
75. Flanagan DE, Evans ML, Nonsod TP, et al. The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003; 284:E313-E316.
76. Chan JL, Bullen J, Lee JH. Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab 2004; 89:335-343.
77. Janssen JA, van der Toorn FM, Hofland LJ, et al. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Eur J Endocrinol 2001; 145:711-716.
78. Iniguez G, Salazar T, Roman R, et al. Effects of the IGF-1/IGFBP3 complex on GH and ghrelin nocturnal concentrations in low birth weight children. Clin Endocrinol 2006; 65:687-692. Mean nocturnal growth hormone AUC decreased while ghrelin AUC increased in prepubertal low birth weight children given recombinant human IGF-l/BP3.
79. DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002; 87:5461-5464.
80. Zhang JV, Ren P-G, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996-999.
81. Wortley KE, Anerderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004; 101:8227-8232.
82. Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 2007; 148:21-26. The study casts doubt on the energy regulatory role of obestatin by finding no effects in rodents of this peptide on food intake, body weight, energy expenditure, locomotion, or respirator quotient, and no hypothalamic mRNA expression of the putative obestatin receptor AGPr-39.
83. Nogueiras R, Tschop M. Separation of conjoined hormones yields appetite rivals. Science 2005; 310:985-986.
84. Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 1973; 245:323-325.
85. Dham S, Banerji MA. The brain-gut axis in regulation of appetite and obesity. Pediatr Endocrinol Rev 2006; 3 (S4):544-554. Concisely reviews the interplay between gut hormones and brain appetite control centers and discusses the role of bariatric surgery effects on the gut-brain axis.
86. Clerc P, Gracia Coll Constans M, Lulka H, et al. Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. Endocrinology 2007; 148:1039-1049. Implies pharmacologic treatment of obesity based on gut hormone replacement must target CCK1 and CCK2 receptors for full physiologic benefit.
87. Smith GP, Jerome C, Cushin BJ, et al. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213:1036-1037.
88. Edwards GL, Ladenheim EE, Ritter RC. Dorsomedial hindbrain participation in cholecystotokinin induced satiety. Am J Physiol 1986; 251:R971-R977.
89. West DB, Fey D, Woods SC. Cholecysotokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984; 246:R776-R787.
90. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 1998; 274:R618-R625.
91. Reidleberger RD, O'Rourke MF. Potent cholecystokinin antagonist L 364718 stimulates food intake in rats. Am J Physiol 1989; 257:R1512-R1518.
92. Ahren B, Holst JJ, Efendic S. Antidiabetogenic action of CCK-8 in type 2 diabetes. J Clin Endocrinol Metab 2000; 85:1043-1048.
93. Druker D. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32. Underscores that enteroendocrine-derived hormones as regulators of glucose homeostasis may play a significant role in obesity related sequelae of glucose intolerance.
94. Hayes MR, Covasa M. Dorsal hindbrain 5-HT3 receptors participate in control of meal size and mediate CCK-induced satiation. Brain Res 2006; 1103:99-107. Implications include that serotonergic influences on appetite may provide new targets for pharmacologic treatment of appetite disorders including obesity, bulimia and anorexia.
95. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 57:S13-S35. Description of CCK levels in the clinical context of obesity. Demonstrates the variability that occurs between moderate and morbidly obese patients.
96. Bowen J, Noakes M, Trenerry C, Clifton PM. Energy intake, ghrelin, and cholecystokinin after different carbohydrate and protein preloads in overweight men. J Clin Endocrinol Metab 2006; 91:1477-1483. Suggests that dietary macronutrient composition regulates satiety and energy intake through a hormonally derived circuit.
97. Hayes MR, Miller CK, Ulbrecht JS, et al. A carbohydrate-restricted diet alters gut peptides and adiposity signals in men and women with metabolic syndrome. J Nutr 2007; 137:1944-1950. Implications for dietary management of obesity to physiologically control appetite and energy intake.
98. Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006; 7:163-182. Excellent overview of current understanding of gut-derived hormones from biochemical origins to clinical implications. Well organized and comprehensive assessment of the literature.
99. Xia Y, Ran L, Yan D. Regulative effects of ovarian steroids on rat gastric motility and sensitivity. Acta Physiol Sin 2006; 58:275-280. Emphasizes that the hormonal milieu of obesity may partly be affected by gender and sex hormones.
100. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136:3585-3596.
101. Blonde L, Rosenstock J, Triplett C. What are incretins, and how will they influence the management of type 2 diabetes? J Manag Care Pharm 2006; 12:S2-S12. Provides an experimental basis for the application of gut derived incretins in targeting glucose homeostasis and the metabolic syndrome.
102. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609-613.
103. D'Alessio DA, Vogel R, Prigeon R, et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996; 97:133-138.
104. Edwards CMB, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48:86-93.
105. Martins C, Morgan LM, Bloom SR, Robertson MD. Effects of exercise on gut peptides, energy intake and appetite. J Endocrinol 2007; 193:251-258. Suggests that exercise and activity may provide beneficial effects on weight not only through energy expenditure, but also through effects on energy intake via perturbations in gut hormone levels.
106. Verdich C, Toubro S, Buemann B, et al. The role of postprandial releases of insulin and incretin hormones in meal induced satiety: effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25:1206-1214.
107. (3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 2005; 25:10510-10519.
108. Le Roux CW, Batterham RL, Aylwin SJB, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147:3-8. Implies that attenuated peptide YY release in obesity may be a pharmacologic target for obesity management.
109. Vazquez Roque MI, Camilleri M, Stephens DA, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology 2006; 131:1717-1724.
110. th NPY meeting. Peptides 2007; 28:198-202. Suggests that PYY action involves vagal afferents as well as direct hypothalamic inputs and that prior conflicting study of PYY action may be a result of this complex interplay.
111. Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93:210-215. Offers biochemical, gut hormone regulated explanations for observed changes in satiety and continued weight control after gastric bypass.
112. 3-36. New Engl J Med 2003; 349:941-948.
113. Boey D, Sainsbury A, Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides 2007; 28:390-395. PYY's role described as not only satiation, but also newfound contribution to glucose homeostasis.
114. Sodowski K, Zwirska-Korczala K, Kuka D, et al. Basal and postprandial gut peptides affecting food intake in lean and obese pregnant women. J Physiol Pharmacol 2007; 58:S37-S52. Emphasizes the importance of research in the hormonal control of weight gain and appetite control in pregnant women-which has future implications for not only the mother's well being, but the progeny's risk of pregnancy related complications and future obesity.
115. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006; 444:854-859.
116. Cohen MA, Ellis SM, Carel W, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88:4696-4701.
117. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized control trial. Int J Obes 2006; 30:1729-1736. Introduces oxyntomodulin as a potential pharmacologic avenue for the treatment of obesity.
118. Hopkins DF, Williams G. Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med 1997; 14:1044-1050.
119. Schwartz MW, Bergman RN, Kahn SE, et al. Evidence for entry of plasma insulin in cerebrospinal fluid through an intermediate compartment in dog. Quantitative aspects and implications for transport. J Clin Invest 1991; 88:1272-1281.
120. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003; 24:1-10.
121. Schartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature 2000; 404:66-671.
122. Oici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8:1376-1382.
123. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289:2122-2125.
124. Kong WM, Martin NM, Smith KL, et al. Triiodothyronine stimulates food intake via the hypothalamic ventromedial nucleus independent of changes in energy expenditure. Endocrinology 2004; 145:5252-5258.
125. Cappola A, Liu ZW, Andrews ZB, et al. A central thermogenic-like mechanism in feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab 2007; 5:21-33.
126. Vay YA, Go LW, Li T, et al. Brainstem thyrotropin-releasing hormone regulates food intake through vagal-dependent cholinergic stimulation of ghrelin secretion. J Clin Endocrinol Metab 2006; 147:6004-6010. Animal studies that explore the role of brainstem TRH in feeding through vagal cholinergic regulation of ghrelin release.
127. Yamada M, Satoh T, Mori M. Mice lacking the thyrotropin-releasing hormone gene: what do they tell us? Thyroid 2003; 13:1111-1121.
128. Makimura H, Mizuno TM, Roberts J, et al. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes 2000; 49:1917-1923.
129. Drazen DL, Wortman MD, Schwartz MW. Adrenalectomy alters the sensitivity of the central nervous system melanocortin system. Diabetes 2003; 52:2928-2934.
130. Gao Q, Mezei G, Nie Y. Anorectic estrogen mimics leptin's effects on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat Med 2007; 13:89-94. Explores the role of estrogen in promoting AMPA glutamate receptors in the hypothalamus that play an important role in potentiation of synaptic plasticity in energy regulating hypothalamic nuclei.
131. Bouret SG, Draper SJ, Simerly RB. Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 2004; 304:108-110.
132. Montague CT, Farooqui IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903-908.
133. Ong KK, Ahmed ML, Sherriff A, et al. Cord blood leptin is associated with size at birth and predicts infancy weight gain in humans. J Clin Endocrinol Metab 1999; 84:1145-1148.
134. Ong KKL, Ahmed ML, Dunger DB. The role of leptin in human growth and puberty. Acta Paediatr Suppl 1999; 433:95-98.
135. Cortelazzi D, Cappiello V, Morpurgos PS, et al. Circulating levels of ghrelin in human fetuses. Eur J Endocrinol 2003; 149:111-116.
136. Onal EE, Cinaz P, Atalay Y, et al. Umbilical cord ghrelin concentrations in small- and appropriate-for-gestational age newborn infants: relationship to anthropomorphic markers. J Endocrinol 2004; 180:267-271.
137. James RJ, Drewett RF, Cheetham TD. Low cord ghrelin levels in term infants are associated with slow weight gain over the first 3 months of life. J Clin Endocrinol Metab 2004; 89:3847-3850.
138. Farquhar J, Heiman M, Wong AC, et al. Elevated umbilical cord ghrelin concentrations in small for gestational age neonates. J Clin Endocrinol Metab 2003; 88:4324-4327.
139. Sivan E, Mazaki-Tovi S, Pariente C, et al. Adiponectin in human cord blood: relation to fetal birth weight and gender. J Clin Endocrinol Metab 2003; 88:5656-5660.
140. Harrington TA, Thomas EL, Modi N, et al. Fast and reproducible method for the direct quantitation of adipose tissue in newborn infants. Lipids 2002; 37:95-100.
141. Cianfarani S, Martinez C, Maiorana A, et al. Adiponectin levels are reduced in children born small for gestational age and are inversely related to postnatal catch-up growth. J Clin Endocrinol Metab 2004; 89:1346-1351.
142. Mazaki-Tov S, Kanety H, Pariente C, et al. Cord blood adiponectin in large-for-gestational age newborns. Am J Obstet Gynecol 2005; 193:1238-1242.
143. Dunger D, Ong K. Abundance of adiponectin in the newborn. Clin Endocrinol 2004; 61:416-417.
144. Bottner A, Kratzsch J, Muller G, et al. Gender differences of adiponectin develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89:4053-4061.
145. Kjaer K, Frystyk J, Ole D, et al. Gender differences of oligomers and toal adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007; 92:1857-1862. Cross-sectional study of concentrations of total and high molecular weight adiponectin in children of different pubertal stages suggests that the decline in adiponectin in males reflects a fall in the high molecular weight isomers.